Pilot Synovial Fluid Molecular/Stem Cell Response to PRP in Knee Osteoarthritis: Clinical & Imaging Outcome Correlation

Inclusion Criteria: 1. Early/Mild to Moderate Stage knee osteoarthritis (KOA), as determined by Kellgren-Lawrence Grade 2 to 3 on PA standing radiograph within the past three months; * A prospective subject who has a diagnosis of non-end stage KOA (i.e., a potential study candidate) and expresses interest in participating but has no XRAY within the specified time-period will be sent for a fresh XRAY. This XRAY will be read by a radiologist \& be paid for by the study. 2. \>=40 years of age; 3. Average 100-point VAS score of \>50, on average, within the past 3 months\*, with KOA felt to be the primary contributor to pain. * Alternate 10-point scales with pain scores averaging \>5 may be considered if the prospective subject also completes a VAS with score \>50 at screening. 4. Exam consistent with KOA being primary etiology of pain; 5. No signs of inflammatory arthropathy in medical record, history or physical examination; 6. A \>3 millimeter intra-articular (IA) effusion present on ultrasound evaluation. 7. \[If a chronic liver or renal disease patient, evidence of stable disease over/within the past six months, else exclusion.\] 8. Veteran receiving care at McGuire VAMC. Exclusion Criteria: 1. Morbid obesity (BMI \>40); 2. Poorly controlled diabetes (hemoglobin A1C \> 7.5 or fasting blood glucose of \>200) in last 6 months; 3. Ipsilateral knee surgery, trauma within last 6 months, or corticosteroid injection within 3 months. 4. 4\. History of inflammatory arthropathy (RA, SLE or crystalline arthritis of the knee)\*\*; 5. Any rheumatoid arthritis or gout diagnosis is exclusionary. 6. Current infection of the affected joint or any other uncontrolled or untreated active infection. 7. Moderate to severe anemia (hemoglobin \< 11 g/dl) or thrombocytopenia (platelet count \< 100,000); Hemoglobin \>17 g/dl or \<11 g/dl and/or platelet counts \>500,000 or \<100,000 platelets/μl. * \[CBC obtained within 6 months will be required, even if obtained at initial screening visit.\] 8. Individuals on dialysis, with liver failure, or uncontrolled renal or liver disease are excluded. * In those with chronic renal or liver disease, documentation of stable disease within the most recent 6 months will be required. 9. Individuals on a therapeutic anticoagulant (e.g., Warfarin, Dabigatran, Enoxaparin) and those with a history of coagulopathy are excluded. * Per standard clinical practice, subjects on anti-platelet therapy are not excluded. 10. Pregnancy or breast-feeding; * Female subjects of child-bearing potential must have a negative pregnancy screen prior to enrollment. * Female subjects of child-bearing potential must confirm they are not actively breast-feeding prior to enrollment. 11. Current illicit drug abuse / active alcohol abuse (i.e, Current substance abuse); 12. Uncontrolled psychiatric disorder; 13. Lack of transportation (i.e., to get to/from appointments at VAMC) and/or willingness to attend study appointments (screening/consent, Intervention, Day10-follow-up, Month-6 follow-up, and then visits over-the-phone / in-person / or via Telehealth for Month-3 and Month-12; 14. Advanced or currently active cancer. 15. Blood disorders (such as Sickle Cell Anemia, TTP, others) 16. Vulnerable populations: Individuals incapable of making informed decisions will not be enrolled, nor will those under some form of incarceration.